# PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

> **NCT03701022** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 61 (estimated)

## Conditions studied

- NK/T-cell Lymphoma

## Interventions

- **DRUG:** SHR1210

## Key facts

- **NCT ID:** NCT03701022
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-20
- **Primary completion:** 2020-03-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03701022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03701022, "PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03701022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*